EASL Clinical Practice Guidelines

References

[1]EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol. 2011; 55: 245264
Abstract | Full Text | Full Text PDF | PubMed | Scopus (519)

[2]Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17: 107115
CrossRef | PubMed | Scopus (192)

[3]Hepatitis, C. Wkly Epidemiol Rec. 1997; 72: 6569
PubMed

[4]Cornberg, M., Razavi, H.A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C. et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011; 31: 3060
CrossRef | PubMed | Scopus (84)

[5]Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe, a review of available epidemiological data. Geneva: European Association for the Study of the, Liver; 2013. www.easl.eu.
www.easl.eu

[6]Rantala M, van de Laar M. Surveillance and epidemiology of hepatitis B and C in Europe a review. Eur Surveill 2008;13(21): <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880>.
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880

[7]Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013. http://dx.doi.org/10.1002/hep.26744 [Epub ahead of print, PubMed PMID: 24115039.].

[8]Antaki, N., Craxi, A., Kamal, S., Moucari, R., Van der Merwe, S., Haffar, S. et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report. Liver Int. 2010; 30: 342355
CrossRef | PubMed | Scopus (65)

[9]Murphy, D., Chamberland, J., Dandavino, R., and Sablon, E. A new genotype of hepatitis C virus originating from central Africa. Hepatology. 2007; 46: 623A

[10]Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., and Hickman, M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011; 54: 11371144
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[11]van de Laar, T.J., Matthews, G.V., Prins, M., and Danta, M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010; 24: 17991812
CrossRef | PubMed | Scopus (60)

[12]Esteban, J.I., Sauleda, S., and Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008; 48: 148162
Abstract | Full Text | Full Text PDF | PubMed | Scopus (183)

[13]Thein, H.H., Yi, Q., Dore, G.J., and Krahn, M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48: 418431
CrossRef | PubMed | Scopus (140)

[14]John-Baptiste, A., Krahn, M., Heathcote, J., Laporte, A., and Tomlinson, G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010; 53: 245251
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[15]Yang, J.D. and Roberts, L.R. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010; 7: 448458
CrossRef | PubMed | Scopus (190)

[16]Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: European Centre for Disease Prevention and Control; 2010.

[17]McDonald, S.A., Hutchinson, S.J., Bird, S.M., Mills, P.R., Dillon, J., Bloor, M. et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res. 2009; 18: 271283
CrossRef | PubMed | Scopus (23)

[18]Grebely, J. and Dore, G.J. What is killing people with hepatitis C virus infection?. Semin Liver Dis. 2011; 31: 331339
CrossRef | PubMed | Scopus (18)

[19]Seeff, L.B. The history of the natural history of hepatitis C (19682009). Liver Int. 2009; 29: 8999
CrossRef | PubMed | Scopus (67)

[20]Mallat, A., Hezode, C., and Lotersztajn, S. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol. 2008; 48: 657665
Abstract | Full Text | Full Text PDF | PubMed | Scopus (39)

[21]Brunet, L., Moodie, E.E., Rollet, K., Cooper, C., Walmsley, S., Potter, M. et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis. 2013; 57: 663670
CrossRef | PubMed

[22]Costentin, C.E., Roudot-Thoraval, F., Zafrani, E.S., Medkour, F., Pawlotsky, J.M., Mallat, A. et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol. 2011; 54: 11231129
Abstract | Full Text | Full Text PDF | PubMed | Scopus (18)

[23]Modi, A.A., Feld, J.J., Park, Y., Kleiner, D.E., Everhart, J.E., Liang, T.J. et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201209
CrossRef | PubMed | Scopus (60)

[24]Ohfuji, S., Fukushima, W., Tanaka, T., Habu, D., Tamori, A., Sakaguchi, H. et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res. 2006; 36: 201208
CrossRef | PubMed | Scopus (33)

[25]Manns, M.P. and von Hahn, T. Novel therapies for hepatitis C one pill fits all?. Nat Rev Drug Discov. 2013; 12: 595610
CrossRef | PubMed

[26]Andrews, J., Guyatt, G., Oxman, A.D., Alderson, P., Dahm, P., Falck-Ytter, Y. et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66: 719725
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[27]Chevaliez, S. and Pawlotsky, J.M. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008; 22: 10311048
Abstract | Full Text | Full Text PDF | PubMed | Scopus (18)

[28]Kamili, S., Drobeniuc, J., Araujo, A.C., and Hayden, T.M. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012; 55: S43S48
CrossRef | PubMed | Scopus (8)

[29]Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T. et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 139: 15931601
Abstract | Full Text | Full Text PDF | PubMed | Scopus (73)

[30]Martinot-Peignoux, M., Stern, C., Maylin, S., Ripault, M.P., Boyer, N., Leclere, L. et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51: 11221126
CrossRef | PubMed | Scopus (42)

[31]Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343350
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1055)

[32]Castera, L., Sebastiani, G., Le Bail, B., de Ledinghen, V., Couzigou, P., and Alberti, A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010; 52: 191198
Abstract | Full Text | Full Text PDF | PubMed | Scopus (66)

[33]Chevaliez, S., Bouvier-Alias, M., Brillet, R., and Pawlotsky, J.M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009; 4: e8209
CrossRef | PubMed | Scopus (49)

[34]Thompson, A.J., Muir, A.J., Sulkowski, M.S., Ge, D., Fellay, J., Shianna, K.V. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139: e118

[35]Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399401
CrossRef | PubMed | Scopus (1686)

[36]Hezode, C., Fontaine, H., Dorival, C., Larrey, D., Zoulim, F., Canva, V. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) NCT01514890. J Hepatol. 2013; 59: 434441
Abstract | Full Text | Full Text PDF | PubMed | Scopus (47)

[37]Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 11951206
CrossRef | PubMed | Scopus (1011)

[38]Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 24052416
CrossRef | PubMed | Scopus (930)

[39]Sherman, K.E., Flamm, S.L., Afdhal, N.H., Nelson, D.R., Sulkowski, M.S., Everson, G.T. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365: 10141024
CrossRef | PubMed | Scopus (335)

[40]Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975982
CrossRef | PubMed | Scopus (4561)

[41]Hadziyannis, S.J., Sette, H. Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346355
CrossRef | PubMed

[42]Manns, M.P., Wedemeyer, H., and Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55: 13501359
CrossRef | PubMed | Scopus (298)

[43]McHutchison, J.G., Lawitz, E.J., Shiffman, M.L., Muir, A.J., Galler, G.W., McCone, J. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580593
CrossRef | PubMed | Scopus (654)

[44]Poordad, F., Bronowicki, J.P., Gordon, S.C., Zeuzem, S., Jacobson, I.M., Sulkowski, M.S. et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012; 143: e601e605
Abstract | Full Text | Full Text PDF | Scopus (40)

[45]Buti M, Agarwal K, Horsmans YJ, Sievert W, Janczewska E, Zeuzem S, et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir vs. administration every 8 h in treatment-naive, genotype 1 HCV infected patients. In: 63rd annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, November 913; 2012 [abstract LB8].

[46]Marcellin, P., Forns, X., Goeser, T., Ferenci, P., Nevens, F., Carosi, G. et al. Telaprevir is effective given every 8 or 12 h with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011; 140: 459468 ([quiz e414])
Abstract | Full Text | Full Text PDF | PubMed | Scopus (106)

[47]Manns, M., Zeuzem, S., Sood, A., Lurie, Y., Cornberg, M., Klinker, H. et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol. 2011; 55: 554563
Abstract | Full Text | Full Text PDF | PubMed | Scopus (20)

[48]Marcellin, P., Cheinquer, H., Curescu, M., Dusheiko, G.M., Ferenci, P., Horban, A. et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012; 56: 20392050
CrossRef | PubMed | Scopus (15)

[49]De Nicola, S., Aghemo, A., Rumi, M.G., Galmozzi, E., Valenti, L., Soffredini, R. et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012; 55: 336342
CrossRef | PubMed | Scopus (31)

[50]Vermehren, J., Kau, A., Gartner, B.C., Gobel, R., Zeuzem, S., and Sarrazin, C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008; 46: 38803891
CrossRef | PubMed | Scopus (48)

[51]Chevaliez, S., Bouvier-Alias, M., Brillet, R., and Pawlotsky, J.M. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007; 46: 2231
CrossRef | PubMed | Scopus (77)

[52]Sarrazin, C., Shiffman, M.L., Hadziyannis, S.J., Lin, A., Colucci, G., Ishida, H. et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol. 2010; 52: 832838
Abstract | Full Text | Full Text PDF | PubMed | Scopus (29)

[53]Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958965
Abstract | Full Text | Full Text PDF | PubMed | Scopus (4734)

[54]Diago, M., Shiffman, M.L., Bronowicki, J.P., Zeuzem, S., Rodriguez-Torres, M., Pappas, S.C. et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 2010; 51: 18971903
CrossRef | PubMed | Scopus (33)

[55]Shiffman, M.L., Suter, F., Bacon, B.R., Nelson, D., Harley, H., Sola, R. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357: 124134
CrossRef | PubMed | Scopus (371)

[56]Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43: 954960
CrossRef | PubMed | Scopus (377)

[57]Ferenci, P., Laferl, H., Scherzer, T.M., Gschwantler, M., Maieron, A., Brunner, H. et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135: 451458
Abstract | Full Text | Full Text PDF | PubMed | Scopus (174)

[58]Berg, T., Sarrazin, C., Herrmann, E., Hinrichsen, H., Gerlach, T., Zachoval, R. et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003; 37: 600609
CrossRef | PubMed | Scopus (222)

[59]Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J. et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44: 97103
Abstract | Full Text | Full Text PDF | PubMed | Scopus (386)

[60]Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., and Albrecht, J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38: 645652
CrossRef | PubMed | Scopus (700)

[61]Mangia, A., Minerva, N., Bacca, D., Cozzolongo, R., Ricci, G.L., Carretta, V. et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008; 47: 4350
CrossRef | PubMed | Scopus (190)

[62]Moreno, C., Deltenre, P., Pawlotsky, J.M., Henrion, J., Adler, M., and Mathurin, P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol. 2010; 52: 2531
Abstract | Full Text | Full Text PDF | PubMed | Scopus (37)

[63]Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs. 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130: 10861097
Abstract | Full Text | Full Text PDF | PubMed | Scopus (414)

[64]Pearlman, B.L., Ehleben, C., and Saifee, S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007; 46: 16881694
CrossRef | PubMed | Scopus (190)

[65]Sanchez-Tapias, J.M., Diago, M., Escartin, P., Enriquez, J., Romero-Gomez, M., Barcena, R. et al. Peginterferon-alfa2a plus ribavirin for 48 vs. 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006; 131: 451460
Abstract | Full Text | Full Text PDF | PubMed | Scopus (312)

[66]Ferenci, P., Laferl, H., Scherzer, T.M., Maieron, A., Hofer, H., Stauber, R. et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010; 138: 503512 ([512 e501])
Abstract | Full Text | Full Text PDF | PubMed | Scopus (73)

[67]Buti, M., Lurie, Y., Zakharova, N.G., Blokhina, N.P., Horban, A., Teuber, G. et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010; 52: 12011207
CrossRef | PubMed | Scopus (43)

[68]Farnik, H., Lange, C.M., Sarrazin, C., Kronenberger, B., Zeuzem, S., and Herrmann, E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol. 2010; 8: 884890
Abstract | Full Text | Full Text PDF | PubMed | Scopus (24)

[69]Dalgard, O., Bjoro, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E. et al. Pegylated interferon alfa and ribavirin for 14 vs. 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008; 47: 3542
CrossRef | PubMed | Scopus (148)

[70]Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 26092617
CrossRef | PubMed | Scopus (497)

[71]von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T. et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129: 522527
Abstract | Full Text | Full Text PDF | PubMed

[72]Yu, M.L., Dai, C.Y., Huang, J.F., Hou, N.J., Lee, L.P., Hsieh, M.Y. et al. A randomised study of peginterferon and ribavirin for 16 vs. 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007; 56: 553559
CrossRef | PubMed | Scopus (188)

[73]Kau, A., Vermehren, J., and Sarrazin, C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49: 634651
Abstract | Full Text | Full Text PDF | PubMed | Scopus (177)

[74]Romero-Gomez, M., Fernandez-Rodriguez, C.M., Andrade, R.J., Diago, M., Alonso, S., Planas, R. et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008; 48: 721727
Abstract | Full Text | Full Text PDF | PubMed | Scopus (86)

[75]Zeuzem, S., Hultcrantz, R., Bourliere, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J. et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40: 993999
Abstract | Full Text | Full Text PDF | PubMed

[76]Berg, T., Shiffman, M.L., Zeuzem, S., Berg, C.P., de Figueiredo-Mendes, C., Dore, G.J. et al. 48 Weeks of peginterferon alfa-2a/ribavirin improves SVR24 and decreases relapse across HCV genotype 2/3 patient subgroups not achieving a rapid virological response: N-CORE study. J Hepatol. 2013; 58: S323
Abstract | Full Text PDF

[77]Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36: S237S244
CrossRef | PubMed

[78]Soza, A., Everhart, J.E., Ghany, M.G., Doo, E., Heller, T., Promrat, K. et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002; 36: 12731279
CrossRef | PubMed | Scopus (144)

[79]Shiffman, M.L., Salvatore, J., Hubbard, S., Price, A., Sterling, R.K., Stravitz, R.T. et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007; 46: 371379
CrossRef | PubMed | Scopus (159)

[80]Afdhal, N.H., Dieterich, D.T., Pockros, P.J., Schiff, E.R., Shiffman, M.L., Sulkowski, M.S. et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 13021311
Abstract | Full Text | Full Text PDF | PubMed | Scopus (259)

[81]Pockros, P.J., Shiffman, M.L., Schiff, E.R., Sulkowski, M.S., Younossi, Z., Dieterich, D.T. et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004; 40: 14501458
CrossRef | PubMed | Scopus (117)

[82]Sulkowski, M.S., Poordad, F., Manns, M.P., Bronowicki, J.P., Rajender Reddy, K., Harrison, S.A. et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013; 57: 974984
CrossRef | PubMed | Scopus (18)

[83]Weiss, J.J., Brau, N., Stivala, A., Swan, T., and Fishbein, D. Review article: adherence to medication for chronic hepatitis C building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009; 30: 1427
CrossRef | PubMed | Scopus (20)

[84]Grebely, J., Matthews, G.V., Hellard, M., Shaw, D., van Beek, I., Petoumenos, K. et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011; 55: 7685
Abstract | Full Text | Full Text PDF | PubMed | Scopus (19)

[85]Marcellin, P., Chousterman, M., Fontanges, T., Ouzan, D., Rotily, M., Varastet, M. et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int. 2011; 31: 516524
CrossRef | PubMed | Scopus (10)

[86]Smith, S.R., Wahed, A.S., Kelley, S.S., Conjeevaram, H.S., Robuck, P.R., and Fried, M.W. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother. 2007; 41: 11161123
CrossRef | PubMed | Scopus (25)

[87]Evon, D.M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C. et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011; 106: 17771786
CrossRef | PubMed | Scopus (17)

[88]Grebely, J., Knight, E., Genoway, K.A., Viljoen, M., Khara, M., Elliott, D. et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010; 22: 270277
CrossRef | PubMed | Scopus (36)

[89]Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D. et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011; 364: 21992207
CrossRef | PubMed | Scopus (82)

[90]Larrey, D., Salse, A., Ribard, D., Boutet, O., Hyrailles-Blanc, V., Niang, B. et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-alpha2a and ribavirin. Clin Gastroenterol Hepatol. 2011; 9: 781785
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[91]Schmidt, C., Schulte, B., Gansefort, D., Goelz, J., Gerken, G., Scherbaum, N. et al. Optimizing HCV therapy: the impact of psychoeducation on retention and SVR in opiate substituted patients. Hepatology. 2011; 54: 821A822A

[92]Lindenburg, C.E., Lambers, F.A., Urbanus, A.T., Schinkel, J., Jansen, P.L., Krol, A. et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011; 23: 2331
CrossRef | PubMed | Scopus (23)

[93]Waizmann, M. and Ackermann, G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat. 2010; 38: 338345
Abstract | Full Text | Full Text PDF | PubMed | Scopus (18)

[94]Grebely, J., Raffa, J.D., Meagher, C., Duncan, F., Genoway, K.A., Khara, M. et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007; 22: 15191525
CrossRef | PubMed | Scopus (52)

[95]Bonkovsky, H.L., Tice, A.D., Yapp, R.G., Bodenheimer, H.C. Jr., Monto, A., Rossi, S.J. et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008; 103: 27572765
CrossRef | PubMed | Scopus (17)

[96]Sylvestre, D.L. and Zweben, J.E. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007; 18: 406410
Abstract | Full Text | Full Text PDF | PubMed | Scopus (50)

[97]Norman, J., Walsh, N.M., Mugavin, J., Stoove, M.A., Kelsall, J., Austin, K. et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduct J. 2008; 5: 8
CrossRef | PubMed | Scopus (23)

[98]Rodis, J.L. and Kibbe, P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010; 33: 368373
CrossRef | PubMed | Scopus (7)

[99]Alavian, S.M. and Aalaei-Andabili, S.H. Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2012; 10: 203 ([author reply 203])
Abstract | Full Text | Full Text PDF | PubMed

[100]Weiss, J.J., Alcorn, M.C., Rabkin, J.G., and Dieterich, D.T. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol. 2012; 56: 503504
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[101]Bressler, B.L., Guindi, M., Tomlinson, G., and Heathcote, J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003; 38: 639644
CrossRef | PubMed | Scopus (278)

[102]Anand, B.S., Currie, S., Dieperink, E., Bini, E.J., Shen, H., Ho, S.B. et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130: 16071616
Abstract | Full Text | Full Text PDF | PubMed | Scopus (76)

[103]Le Lan, C., Guillygomarch, A., Danielou, H., Le Dreau, G., Laine, F., Vedeilhie, C. et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol. 2012; 56: 334340
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[104]Bruggmann, P., Dampz, M., Gerlach, T., Kravecz, L., and Falcato, L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010; 110: 167171
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[105]Siu, L., Foont, J., and Wands, J.R. Hepatitis C virus and alcohol. Semin Liver Dis. 2009; 29: 188199
CrossRef | PubMed | Scopus (20)

[106]Serfaty, L., Forns, X., Goeser, T., Ferenci, P., Nevens, F., Carosi, G. et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut. 2012; 61: 14731480
CrossRef | PubMed | Scopus (20)

[107]Harrison, S.A., Hamzeh, F.M., Han, J., Pandya, P.K., Sheikh, M.Y., and Vierling, J.M. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012; 56: 464473
CrossRef | PubMed | Scopus (15)

[108]Thevenot, T., Cadranel, J.F., Di Martino, V., Pariente, A., Causse, X., Renou, C. et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology. 2007; 45: 377383
CrossRef | PubMed | Scopus (25)

[109]Stickel, F., Helbling, B., Heim, M., Geier, A., Hirschi, C., Terziroli, B. et al. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat. 2012; 19: 7787
CrossRef | PubMed | Scopus (5)

[110]Alavian, S.M., Tabatabaei, S.V., and Behnava, B. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. J Viral Hepat. 2012; 19: 8893
CrossRef | PubMed | Scopus (12)

[111]Poordad, F., Lawitz, E.J., Reddy, K.R., Afdhal, N.H., Hzode, C., Zeuzem, S. et al. A randomized trial comparing ribavirin dose reduction vs. erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol. 2012; 56: S559
Abstract | Full Text PDF

[112]Tandon, P., Doucette, K., Fassbender, K., Vandermeer, B., Durec, T., and Dryden, D.M. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. J Viral Hepat. 2011; 18: e381e393
CrossRef | PubMed | Scopus (5)

[113]McHutchison, J.G., Dusheiko, G., Shiffman, M.L., Rodriguez-Torres, M., Sigal, S., Bourliere, M. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357: 22272236
CrossRef | PubMed | Scopus (241)

[114]Homeida, S., Ebdon, C., Batty, P., Jackson, B., Kolade, S., Bateman, C. et al. New thrombopoietin receptor agonists for platelet disorders. Drugs Today (Barc). 2012; 48: 293301
PubMed

[115]Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S. et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57: 13791390
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[116]Dalgard, O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis. 2005; 40: S336S338
CrossRef | PubMed | Scopus (56)

[117]Backmund, M., Meyer, K., and Edlin, B.R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis. 2004; 39: 15401543
CrossRef | PubMed | Scopus (63)

[118]Currie, S.L., Ryan, J.C., Tracy, D., Wright, T.L., George, S., McQuaid, R. et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008; 93: 148154
Abstract | Full Text | Full Text PDF | PubMed | Scopus (25)

[119]Grebely, J., Pham, S.T., Matthews, G.V., Petoumenos, K., Bull, R.A., Yeung, B. et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012; 55: 10581069
CrossRef | PubMed | Scopus (14)

[120]Grebely, J., Knight, E., Ngai, T., Genoway, K.A., Raffa, J.D., Storms, M. et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol. 2010; 25: 12811284
CrossRef | PubMed | Scopus (25)

[121]Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 12071217
CrossRef | PubMed | Scopus (716)

[122]Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 24172428
CrossRef | PubMed | Scopus (673)

[123]Flamm, S.L., Lawitz, E., Jacobson, I., Bourliere, M., Hezode, C., Vierling, J.M. et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013; 11: 81 ([e84; quiz e85])
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[124]Singal, A.G., Volk, M.L., Jensen, D., Di Bisceglie, A.M., and Schoenfeld, P.S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010; 8: 280288 ([288 e281])
Abstract | Full Text | Full Text PDF | PubMed | Scopus (79)

[125]van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 25842593
CrossRef | PubMed | Scopus (53)

[126]Schmid, M., Kreil, A., Jessner, W., Homoncik, M., Datz, C., Gangl, A. et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut. 2005; 54: 10141020
CrossRef | PubMed | Scopus (37)

[127]Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M. et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680687
CrossRef | PubMed | Scopus (277)

[128]Forns, X., Garcia-Retortillo, M., Serrano, T., Feliu, A., Suarez, F., de la Mata, M. et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39: 389396
Abstract | Full Text | Full Text PDF | PubMed | Scopus (208)

[129]Carrion, J.A., Martinez-Bauer, E., Crespo, G., Ramirez, S., Perez-del-Pulgar, S., Garcia-Valdecasas, J.C. et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009; 50: 719728
Abstract | Full Text | Full Text PDF | PubMed | Scopus (75)

[130]Everson, G.T., Trotter, J., Forman, L., Kugelmas, M., Halprin, A., Fey, B. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005; 42: 255262
CrossRef | PubMed | Scopus (251)

[131]Prieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D. et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29: 250256
CrossRef | PubMed | Scopus (385)

[132]Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., and Lucey, M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122: 889896
Abstract | Full Text | Full Text PDF | PubMed

[133]Berenguer, M., Palau, A., Aguilera, V., Rayon, J.M., Juan, F.S., and Prieto, M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008; 8: 679687
CrossRef | PubMed | Scopus (100)

[134]Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004; 41: 830836
Abstract | Full Text | Full Text PDF | PubMed | Scopus (200)

[135]Blasco, A., Forns, X., Carrion, J.A., Garcia-Pagan, J.C., Gilabert, R., Rimola, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006; 43: 492499
CrossRef | PubMed | Scopus (139)

[136]Samuel, D., Bizollon, T., Feray, C., Roche, B., Ahmed, S.N., Lemonnier, C. et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003; 124: 642650
Abstract | Full Text | Full Text PDF | PubMed | Scopus (282)

[137]Carrion, J.A., Navasa, M., Garcia-Retortillo, M., Garcia-Pagan, J.C., Crespo, G., Bruguera, M. et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 17461756
Abstract | Full Text | Full Text PDF | PubMed | Scopus (193)

[138]Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49: 274287
Abstract | Full Text | Full Text PDF | PubMed | Scopus (124)

[139]Selzner, N., Guindi, M., Renner, E.L., and Berenguer, M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011; 55: 207217
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[140]Garg, V., van Heeswijk, R., Lee, J.E., Alves, K., Nadkarni, P., and Luo, X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54: 2027
CrossRef | PubMed | Scopus (124)

[141]Hulskotte, E., Gupta, S., Xuan, F., van Zutven, M., OMara, E., Feng, H.P. et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012; 56: 16221630
CrossRef | PubMed | Scopus (30)

[142]Coilly, A., Roche, B., Botta-Fridlund, D., Leroy, V., Pageaux, P., Si-Ahmed, S. et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol. 2012; 56: S21
Abstract | Full Text PDF

[143]Qurishi, N., Kreuzberg, C., Luchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T. et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003; 362: 17081713
Abstract | Full Text | Full Text PDF | PubMed | Scopus (341)

[144]Solas, C., Pambrun, E., Winnock, M., Salmon, D., Poizot-Martin, I., Dominguez, S. et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?. AIDS. 2012; 26: 21932199
CrossRef | PubMed | Scopus (2)

[145]Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J., Palu, G. et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005; 42: 615624
Abstract | Full Text | Full Text PDF | PubMed | Scopus (232)

[146]Opravil, M., Rodriguez-Torres, M., Rockstroh, J., Snoeck, E., Chung, R.T., Tietz, A. et al. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. HIV Clin Trials. 2012; 13: 3345
CrossRef | PubMed | Scopus (3)

[147]Rodriguez-Torres, M., Slim, J., Bhatti, L., Sterling, R., Sulkowski, M., Hassanein, T. et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012; 13: 142152
CrossRef | PubMed | Scopus (11)

[148]Dieterich D, Soriano V, Sherman K, Girard P-M, Rockstroh J, Adiwijaya B, et al. Telaprevir in combination with pegylated interferon-alfa-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. In: 19th conference on retroviruses and opportunistic infections, seattle, WA, March 58; 2012 [abstract 46].

[149]Sulkowski, M., Pol, S., Mallolas, J., Fainboim, H., Cooper, C., Slim, J. et al. Boceprevir vs. placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013; 13: 597605
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[150]Kiser, J.J., Burton, J.R., Anderson, P.L., and Everson, G.T. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012; 55: 16201628
CrossRef | PubMed | Scopus (56)

[151]European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011; 25: 399409
PubMed

[152]Potthoff, A., Wedemeyer, H., Boecher, W.O., Berg, T., Zeuzem, S., Arnold, J. et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008; 49: 688694
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[153]Potthoff, A., Berg, T., and Wedemeyer, H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009; 44: 14871490
CrossRef | PubMed | Scopus (7)

[154]Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S., and Martin, P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003; 18: 10711081
CrossRef | PubMed | Scopus (94)

[155]Liu, C.H., Liang, C.C., Lin, J.W., Chen, S.I., Tsai, H.B., Chang, C.S. et al. Pegylated interferon alpha-2a vs. standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008; 57: 525530
CrossRef | PubMed | Scopus (39)

[156]Peck-Radosavljevic, M., Boletis, J., Besisik, F., Ferraz, M.L., Alric, L., Samuel, D. et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol. 2011; 9: 242248
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[157]Liu, C.H., Liang, C.C., Liu, C.J., Tsai, H.B., Hung, P.H., Hsu, S.J. et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut. 2009; 58: 314316
CrossRef | PubMed | Scopus (16)

[158]Treitel, M., Marbury, T., Preston, R.A., Triantafyllou, I., Feely, W., OMara, E. et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012; 51: 619628
CrossRef | PubMed

[159]van Heeswijk, R., Vandevoorde, A., Boogaerts, G., De Paepe, E., van Solingen-Ristea, R., Garg, V. et al. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol. 2011; 54: S492
Abstract | Full Text PDF

[160]Basu, P.P., Siriki, R., Shah, N.J., Farhat, S., Mittimani, K., Atluri, S. et al. Telaprevir with adjusted dose of ribavirin in nave CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C (RCT). J Hepatol. 2013; 58: S30S31
Abstract | Full Text PDF

[161]Scott, D.R., Wong, J.K., Spicer, T.S., Dent, H., Mensah, F.K., McDonald, S. et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010; 90: 11651171
CrossRef | PubMed | Scopus (20)

[162]Gane, E. and Pilmore, H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74: 427437
CrossRef | PubMed

[163]Van Wagner, L.B., Baker, T., Ahya, S.N., Norvell, J.P., Wang, E., and Levitsky, J. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol. 2009; 51: 874880
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[164]Martin, P. and Fabrizi, F. Hepatitis C virus and kidney disease. J Hepatol. 2008; 49: 613624
Abstract | Full Text | Full Text PDF | PubMed | Scopus (37)

[165]Orens, J.B., Estenne, M., Arcasoy, S., Conte, J.V., Corris, P., Egan, J.J. et al. International guidelines for the selection of lung transplant candidates: 2006 update a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25: 745755
Abstract | Full Text | Full Text PDF | PubMed | Scopus (466)

[166]Grebely, J., Raffa, J.D., Lai, C., Kerr, T., Fischer, B., Krajden, M. et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011; 18: 3241
CrossRef | PubMed | Scopus (12)

[167]Darke, S., Kaye, S., and Duflou, J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction. 2006; 101: 17711777
CrossRef | PubMed | Scopus (25)

[168]Shepard, C.W., Finelli, L., and Alter, M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558567
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1231)

[169]Hagan, H., Pouget, E.R., Des Jarlais, D.C., and Lelutiu-Weinberger, C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008; 168: 10991109
CrossRef | PubMed | Scopus (43)

[170]Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378: 571583
Abstract | Full Text | Full Text PDF | PubMed | Scopus (154)

[171]Pybus, O.G., Cochrane, A., Holmes, E.C., and Simmonds, P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol. 2005; 5: 131139
CrossRef | PubMed | Scopus (71)

[172]van Asten, L., Verhaest, I., Lamzira, S., Hernandez-Aguado, I., Zangerle, R., Boufassa, F. et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004; 189: 292302
CrossRef | PubMed | Scopus (78)

[173]de Bruijne, J., Schinkel, J., Prins, M., Koekkoek, S.M., Aronson, S.J., van Ballegooijen, M.W. et al. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol. 2009; 47: 38323838
CrossRef | PubMed | Scopus (19)

[174]van den Berg, C.H., Smit, C., Bakker, M., Geskus, R.B., Berkhout, B., Jurriaans, S. et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007; 22: 183193
CrossRef | PubMed | Scopus (48)

[175]Mehta, S.H., Astemborski, J., Kirk, G.D., Strathdee, S.A., Nelson, K.E., Vlahov, D. et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis. 2011; 203: 587594
CrossRef | PubMed | Scopus (37)

[176]Patrick, D.M., Tyndall, M.W., Cornelisse, P.G., Li, K., Sherlock, C.H., Rekart, M.L. et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001; 165: 889895
PubMed

[177]Maher, L., Li, J., Jalaludin, B., Chant, K.G., and Kaldor, J.M. High hepatitis C incidence in new injecting drug users: a policy failure?. Aust N Z J Public Health. 2007; 31: 3035
CrossRef | PubMed | Scopus (69)

[178]Kim, C., Kerr, T., Li, K., Zhang, R., Tyndall, M.W., Montaner, J.S. et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009; 9: 270
CrossRef | PubMed | Scopus (13)

[179]Roy, E., Alary, M., Morissette, C., Leclerc, P., Boudreau, J.F., Parent, R. et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS. 2007; 18: 2327
CrossRef | PubMed | Scopus (39)

[180]Bruneau, J., Daniel, M., Kestens, Y., Abrahamowicz, M., and Zang, G. Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: results from a cohort study. Int J Drug Policy. 2010; 21: 477484
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5)

[181]Aitken, C., Lewis, J., Hocking, J., Bowden, D., and Hellard, M. Does information about IDUs injecting networks predict exposure to the hepatitis C virus?. Hepat Monthly. 2009; 9: 1723

[182]Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N. et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011; 106: 19781988
CrossRef | PubMed | Scopus (36)

[183]Rehm, J., Frick, U., Hartwig, C., Gutzwiller, F., Gschwend, P., and Uchtenhagen, A. Mortality in heroin-assisted treatment in Switzerland 19942000. Drug Alcohol Depend. 2005; 79: 137143
Abstract | Full Text | Full Text PDF | PubMed | Scopus (39)

[184]Kreek, M.J., Dodes, L., Kane, S., Knobler, J., and Martin, R. Long-term methadone maintenance therapy: effects on liver function. Ann Intern Med. 1972; 77: 598602
CrossRef | PubMed

[185]Petry, N.M., Bickel, W.K., Piasecki, D., Marsch, L.A., and Badger, G.J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000; 9: 265269
CrossRef | PubMed

[186]Andreu, V., Mas, A., Bruguera, M., Salmeron, J.M., Moreno, V., Nogue, S. et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998; 29: 394397
Abstract | Full Text PDF | PubMed | Scopus (110)

[187]Karch, S.B., Stephens, B.G., and Ho, C.H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999; 44: 359368
PubMed

[188]Hezode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E.S. et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005; 42: 6371
CrossRef | PubMed | Scopus (142)

[189]Hezode, C., Zafrani, E.S., Roudot-Thoraval, F., Costentin, C., Hessami, A., Bouvier-Alias, M. et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008; 134: 432439
Abstract | Full Text | Full Text PDF | PubMed | Scopus (81)

[190]Ostapowicz, G., Watson, K.J., Locarnini, S.A., and Desmond, P.V. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998; 27: 17301735
CrossRef | PubMed | Scopus (193)

[191]Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J. et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012; 55: 4957
CrossRef | PubMed | Scopus (38)

[192]Dore, G.J., Hellard, M., Matthews, G.V., Grebely, J., Haber, P.S., Petoumenos, K. et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010; 138: e121e122
Abstract | Full Text | Full Text PDF | Scopus (61)

[193]Alvarez-Uria, G., Day, J.N., Nasir, A.J., Russell, S.K., and Vilar, F.J. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009; 29: 10511055
CrossRef | PubMed | Scopus (16)

[194]Conway, B., Grebely, J., Tossonian, H., Lefebvre, D., and de Vlaming, S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis. 2005; 41: S73S78
CrossRef | PubMed | Scopus (12)

[195]Grebely, J., Genoway, K.A., Raffa, J.D., Dhadwal, G., Rajan, T., Showler, G. et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008; 93: 141147
Abstract | Full Text | Full Text PDF | PubMed | Scopus (76)

[196]Doab, A., Treloar, C., and Dore, G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005; 40: S313S320
CrossRef | PubMed | Scopus (68)

[197]Kramer, J.R., Kanwal, F., Richardson, P., Giordano, T.P., Petersen, L.A., and El-Serag, H.B. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011; 106: 483491
CrossRef | PubMed | Scopus (16)

[198]Gidding, H.F., Law, M.G., Amin, J., Macdonald, G.A., Sasadeusz, J.J., Jones, T.L. et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust. 2011; 194: 398402
PubMed

[199]Bini, E.J., Brau, N., Currie, S., Shen, H., Anand, B.S., Hu, K.Q. et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005; 100: 17721779
CrossRef | PubMed | Scopus (95)

[200]Kanwal, F., Hoang, T., Spiegel, B.M., Eisen, S., Dominitz, J.A., Gifford, A. et al. Predictors of treatment in patients with chronic hepatitis C infection role of patient vs. nonpatient factors. Hepatology. 2007; 46: 17411749
CrossRef | PubMed | Scopus (58)

[201]Robaeys, G., Van Vlierberghe, H., Mathei, C., Van Ranst, M., Bruckers, L., and Buntinx, F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006; 18: 159166
CrossRef | PubMed | Scopus (60)

[202]Hellard, M., Sacks-Davis, R., and Gold, J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009; 49: 561573
CrossRef | PubMed | Scopus (72)

[203]Papadopoulos, V., Gogou, A., Mylopoulou, T., and Mimidis, K. Should active injecting drug users receive treatment for chronic hepatitis C?. Arq Gastroenterol. 2010; 47: 238241
CrossRef | PubMed | Scopus (4)

[204]Manolakopoulos, S., Deutsch, M.J., Anagnostou, O., Karatapanis, S., Tiniakou, E., Papatheodoridis, G.V. et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int. 2010; 30: 14541460
CrossRef | PubMed | Scopus (9)

[205]Bruggmann, P., Falcato, L., Dober, S., Helbling, B., Keiser, O., Negro, F. et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008; 15: 747752
CrossRef | PubMed | Scopus (35)

[206]Sasadeusz, J.J., Dore, G., Kronborg, I., Barton, D., Yoshihara, M., and Weltman, M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction. 2011; 106: 977984
CrossRef | PubMed | Scopus (13)

[207]Sylvestre, D.L., Litwin, A.H., Clements, B.J., and Gourevitch, M.N. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005; 29: 159165
Abstract | Full Text | Full Text PDF | PubMed | Scopus (64)

[208]Mauss, S., Berger, F., Goelz, J., Jacob, B., and Schmutz, G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004; 40: 120124
CrossRef | PubMed | Scopus (135)

[209]van Heeswijk, R., Vandevoorde, A., Verboven, P., Boogaerts, G., De Paepe, E., van Solingen-Ristea, R. et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. J Hepatol. 2011; 54: S491S492
Abstract | Full Text PDF

[210]Luo, X., Trevejo, J., Van Heeswijk, R., and Garg, V. No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers. Global Antivir J. 2011; 7: 116117

[211]Hulskotte, E., Feng, H., Bruce, R., Webster, L., Xuan, F., Lin, W. et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. J Gastroenterol Hepatol. 2012; 27: 169170

[212]Burger, D., Back, D., Buggisch, P., Buti, M., Craxi, A., Foster, G. et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013; 58: 792800
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[213]Van Heeswijk R, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. In: Fifth international workshop on clinical pharmacology of hepatitis therapy, Boston, MA, June 2324; 2010 [abstract 12].

[214]Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, OMara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 48; 2011 [poster 121].

[215]Garg V, Chandorkar G, Smith F, Alves K, van Heeswijk R. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. In: Sixth International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 2223; 2011 [abstract PK_12].

[216]Luo X, Van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, cambridge, MA, June 2223; 2011 [abstract PK_11].

[217]Maurer, H.H., Sauer, C., and Theobald, D.S. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit. 2006; 28: 447453
CrossRef | PubMed | Scopus (50)

[218]Robaeys, G., Grebely, J., Mauss, S., Bruggmann, P., Moussalli, J., De Gottardi, A. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013; 57: S129S137
CrossRef | PubMed | Scopus (4)

[219]Mauss, S. and Klinker, H. Drug-Drug interactions in the treatment of HCV among people who inject drugs. Clin Infect Dis. 2013; 57: S125S128
CrossRef | PubMed | Scopus (1)

[220]Robaeys, G., Nevens, F., Starkel, P., Colle, I., Van Eyken, P., Bruckers, L. et al. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection. Transplant Proc. 2009; 41: 589594
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[221]De Gottardi, A., Hilleret, M.N., Gelez, P., La Mura, V., Guillaud, O., Majno, P. et al. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome. Clin Transplant. 2010; 24: 564571
CrossRef | PubMed | Scopus (1)

[222]Mir, J.M., Laguno, M., Moreno, A., and Rimola, A. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?. J Hepatol. 2006; 44: S140S145
Abstract | Full Text | Full Text PDF | PubMed | Scopus (38)

[223]Ranney, D.N., Acker, W.B., Al-Holou, S.N., Ehrlichman, L., Lee, D.S., Lewin, S.A. et al. Marijuana use in potential liver transplant candidates. Am J Transplant. 2009; 9: 280285
CrossRef | PubMed | Scopus (11)

[224]Webb, K., Shepherd, L., and Neuberger, J. Illicit drug use and liver transplantation: is there a problem and what is the solution?. Transpl Int. 2008; 21: 923929
CrossRef | PubMed | Scopus (2)

[225]Kanchana, T.P., Kaul, V., Manzarbeitia, C., Reich, D.J., Hails, K.C., Munoz, S.J. et al. Liver transplantation for patients on methadone maintenance. Liver Transpl. 2002; 8: 778782
CrossRef | PubMed | Scopus (26)

[226]Koch, M. and Banys, P. Liver transplantation and opioid dependence. JAMA. 2001; 285: 10561058
CrossRef | PubMed

[227]Liu, L.U., Schiano, T.D., Lau, N., ORourke, M., Min, A.D., Sigal, S.H. et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant. 2003; 3: 12731277
CrossRef | PubMed | Scopus (30)

[228]Murray, K.F. and Carrithers, R.L. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005; 41: 14071432
CrossRef | PubMed | Scopus (263)

[229]Harmatz, P., Jonas, M.M., Kwiatkowski, J.L., Wright, E.C., Fischer, R., Vichinsky, E. et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008; 93: 12471251
CrossRef | PubMed | Scopus (24)

[230]Strader, D.B., Wright, T., Thomas, D.L., and Seeff, L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39: 11471171
CrossRef | PubMed | Scopus (1262)

[231]Mondelli, M.U., Cerino, A., and Cividini, A. Acute hepatitis C: diagnosis and management. J Hepatol. 2005; 42: S108S114
Abstract | Full Text | Full Text PDF | PubMed | Scopus (43)

[232]Dienstag, J.L. Reply. Gastroenterology. 2006; 131: 332333
Abstract | Full Text | Full Text PDF | PubMed

[233]Kamal, S.M. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008; 103: 12831297 ([quiz 1298])
CrossRef | PubMed | Scopus (50)

[234]Santantonio, T., Wiegand, J., and Gerlach, J.T. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008; 49: 625633
Abstract | Full Text | Full Text PDF | PubMed | Scopus (59)

[235]Wiegand, J., Jackel, E., Cornberg, M., Hinrichsen, H., Dietrich, M., Kroeger, J. et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004; 40: 98107
CrossRef | PubMed | Scopus (63)

[236]Deterding, K., Gruner, N., Buggisch, P., Wiegand, J., Galle, P.R., Spengler, U. et al. Delayed vs. immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013; 13: 497506
Abstract | Full Text | Full Text PDF | PubMed

[237]Micallef, J.M., Kaldor, J.M., and Dore, G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13: 3441
CrossRef | PubMed | Scopus (250)

[238]Gerlach, J.T., Diepolder, H.M., Zachoval, R., Gruener, N.H., Jung, M.C., Ulsenheimer, A. et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003; 125: 8088
Abstract | Full Text | Full Text PDF | PubMed | Scopus (381)

[239]Poynard, T., Regimbeau, C., Myers, R.P., Thevenot, T., Leroy, V., Mathurin, P. et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2002; DOI: http://dx.doi.org/10.1002/14651858CD000369
http://dx.doi.org/10.1002/14651858CD000369 | CrossRef

[240]Camma, C., Licata, A., Cabibbo, G., Latteri, F., and Craxi, A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother. 2005; 6: 399408
CrossRef | PubMed | Scopus (17)

[241]Hofer, H., Watkins-Riedel, T., Janata, O., Penner, E., Holzmann, H., Steindl-Munda, P. et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003; 37: 6064
CrossRef | PubMed | Scopus (151)